Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis
References (0)
Cited by (89)
EASL Clinical Practice Guidelines on hepatitis delta virus
2023, Journal of HepatologyAutoimmune serology testing in clinical practice: An updated roadmap for the diagnosis of autoimmune hepatitis
2023, European Journal of Internal MedicineCitation Excerpt :Although anti-LKM3 antibodies have been initially described in up to 13% of patients with chronic hepatitis delta [52], they have also been reported in about 5–10% of AIH-2 patients [48,53]. The major target-autoantigens of anti-LKM3 are members of the family 1 uridine diphosphate glucuronosyl-transferases (Table 2) [53]. Anti-LC1 antibodies are detected in about one-third of AIH-2 patients (coexistence with anti-LKM1 in approximately 50% of cases) [18,21,22,54,55].
Impact of genetic and environmental factors on autoimmune hepatitis
2021, Journal of Translational AutoimmunityHepatitis
2019, The Autoimmune DiseasesThe clinical usage and definition of autoantibodies in immune-mediated liver disease: A comprehensive overview
2018, Journal of AutoimmunityCitation Excerpt :Anti-LKM3 was first reported by Rizzetto's group in association with chronic hepatitis delta infection, where it is found in some 13% of patients [104]. It stains hepatocyte cytoplasm and proximal renal tubules of human and primate tissue sections, thus hampering its testing in clinical practice, although it has been described in up to 19% of AIH type 2 patients, at times as the only serological marker [105–107]. The target antigen is family 1 uridine 5′-diphosphate glucuronosyltransferase (UGT-1) [106].
Cutting edge issues in autoimmune hepatitis
2016, Journal of Autoimmunity